Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
The US Food and Drug Administration had twice rejected AstraZeneca’s applications for Lokelma due to issues at the manufacturing plant in Texas
Jeff Holden has become the latest top-level executive to leave, meaning more than a dozen have now left the taxi-hailing app over the past year
The FTSE 100-drugs giant expects product sales, which have been in decline for a while now, to return to growth this year
Trading is in-line so far this year, but that’s not good enough when there is so much growth baked into the Fevertree share price
Wanda’s patient monitoring technology led to the number of congestive heart failure patients being readmitted to hospital almost halving
The political consulting group has struggled to attract new business in the wake of the Trump-Facebook data scandal earlier this year
The investment group has stakes in ten companies, including Horse Hill Developments, Engage Technology and Fresho
The oilfield services group is looking to bounce back from a tough 2017, when it was forced to suspend its chief operating officer amid a Serious Fraud Office investigation
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now